The latest price target for Immunic (NASDAQ:IMUX) was reported by D. Boral Capital on January 7, 2025. The analyst firm set a price target for $17.00 expecting IMUX to rise to within 12 months (a possible 1583.17% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Immunic (NASDAQ:IMUX) was provided by D. Boral Capital, and Immunic maintained their buy rating.

There is no last upgrade for Immunic

The last downgrade for Immunic Inc happened on October 21, 2022 when SVB Leerink changed their price target from $9 to $5 for Immunic Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on January 7, 2025 so you should expect the next rating to be made available sometime around January 7, 2026.

While ratings are subjective and will change, the latest Immunic (IMUX) rating was a maintained with a price target of $17.00 to $17.00. The current price Immunic (IMUX) is trading at is $1.01, which is out of the analyst’s predicted range.